Abstract

PurposeUsing exome sequencing, the underlying variants in many persons with autosomal recessive diseases remain undetected. We explored autosomal recessive Stargardt disease (STGD1) as a model to identify the missing heritability. MethodsSequencing of ABCA4 was performed in 8 STGD1 cases with one variant and p.Asn1868Ile in trans, 25 cases with one variant, and 3 cases with no ABCA4 variant. The effect of intronic variants was analyzed using in vitro splice assays in HEK293T cells and patient-derived fibroblasts. Antisense oligonucleotides were used to correct splice defects. ResultsIn 24 of the probands (67%), one known and five novel deep-intronic variants were found. The five novel variants resulted in messenger RNA pseudoexon inclusions, due to strengthening of cryptic splice sites or by disrupting a splicing silencer motif. Variant c.769-784C>T showed partial insertion of a pseudoexon and was found in cis with c.5603A>T (p.Asn1868Ile), so its causal role could not be fully established. Variant c.4253+43G>A resulted in partial skipping of exon 28. Remarkably, antisense oligonucleotides targeting the aberrant splice processes resulted in (partial) correction of all splicing defects. ConclusionOur data demonstrate the importance of assessing noncoding variants in genetic diseases, and show the great potential of splice modulation therapy for deep-intronic variants.

Highlights

  • In the past decade, next-generation sequencing (NGS) has enabled a rapid identification of novel disease genes,[1,2,3] and transformed molecular diagnostic testing.[4,5,6] far, the emphasis was on coding and flanking splice site sequences that harbor the majority of genetic defects

  • The five novel variants resulted in messenger RNA pseudoexon inclusions, due to strengthening of cryptic splice sites or by disrupting a splicing silencer motif

  • Our data demonstrate the importance of assessing noncoding variants in genetic diseases, and show the great potential of splice modulation therapy for deep-intronic variants

Read more

Summary

Introduction

Next-generation sequencing (NGS) has enabled a rapid identification of novel disease genes,[1,2,3] and transformed molecular diagnostic testing.[4,5,6] far, the emphasis was on coding and flanking splice site sequences that harbor the majority of genetic defects. For diseases that are due to variants in a single gene, the yield of variants generally exceeds 50%. This is true for Stargardt disease (STGD1) (MIM 248200), which is caused by pathogenic variants in the gene encoding the adenosine triphosphate (ATP) binding cassette type A4 (ABCA4)

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call